UKHSA Diagnostic and Research Framework (DRF)

Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security AgencycontractFind a TenderRef ocds-h6vhtk-05d7abProcurement Act 2023SME suitableVCSE suitableclosed for bids
View buyer

Estimated value

£6.3bn

goods

Awarded value

Suppliers

0

Lots

2

0 awarded

Published

12 Mar 2026

Deadline 08 Apr 2026

Description

The UKHSA Diagnostics and Research Open Framework is the successor to the current UKHSA National Microbiology Framework, and predecessor PHE Public Health Microbiology Framework and will be used to support the UK Health Security Agency’s Diagnostics and Research activities for both day to day and incident response. (Please note that it is the potential surge capacity that accounts for the high maximum value of this framework, not anticipated spend) The framework is divided into two lots: Lot One: Diagnostics Goods and Services (products that are UKCA/CE marked or otherwise validated to the required specification), and Lot Two: Research and development (research products that are not UKCA/CE marked) The maximum value (ex VAT) of the framework is set at £6.25 billion The value of Lot 1 is estimated as £5.2b and the value of Lot 2 is estimated as £1.05b. The actual values will vary based on the level of purchasing necessary to provide suitable solutions to the UK’s health protection needs. The maximum value is based on the potential total amount payable exclusive of VAT as estimated by UKHSA, including any potential extension options for call-off contracts. This figure allows for the possibility that a health emergency may occur, such as a pandemic; therefore, the total value of cumulative call-off contracts may be less depending on the potential materialisation of health threats. The value and explanation of how it has been estimated is given in good faith as a guide. It should not be interpreted as an undertaking to purchase any goods or services to any value and does not form part of the Contract.

Scope

Reference
C426524
Total value
£6,250,000,000 excluding VAT
£7,500,000,000 including VAT
Above the relevant threshold
Commercial tool
Standalone contract
Contract dates
23 Jul 2026 to 23 Jul 2028
Possible extension to 23 Jul 2029

each framework in the scheme is expected to run for two years with the option to extend by one year. The end date of any extension is not expected to run past the 8-year mkaximum term

Main category
goods
CPV classifications
33124000
33100000
33600000
38430000
38431000
38433100
38434000
38434500
38434510
38434520
38434540
38434550
38434570
38434580
38436100
38950000
50400000
85148000
50410000
50411000
71900000
50412000
50413000
50430000
50433000
73111000
85111800
85145000
Contract locations
UK, United Kingdom
Particular suitability
Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)

Award criteria

Criteria the buyer will use to evaluate bids.

NameDescriptionTypeWeighting
Meet minimum requirements for whichever lot(s) you are applying for - see ITTquality

Participation

Conditions suppliers must meet to bid.

Conditions of participation are fully detailed within the procurement documents accessible via the Authority's e-procurement portal Atamis

Must be able to provide t least one appropriately certified, accredited or licenced products or services described in the Lot Specific Requirements which are fully detailed within the procurement documents accessible via the Authority's e-procurement portal Atamis

Submission & procedure

Enquiry deadline
24 Mar 2026, 10:00 am
Submission deadline
08 Apr 2026, 9:00 am
Submission address
Application is via submission of a tender response by the deadline stated above via the Health Family’s e-Sourcing Portal, Atamis, Ref C426524 UKHSA Diagnostics and Research Open Framework. https://atamis-1928.my.site.com/s/Welcome
Electronic submission
Yes
Procedure
Open procedure

Lots · 2 total

Divisions of the contract. Each lot can be awarded separately.

View all →
LotTitleEst. valueStatus
1In-vitro diagnostic medical devices and associated services£5.2bnactive
2Goods and services mainly for research & development, experimentation & study£1.1bnactive